17 Mar 2026 Avacta Announces Preclinical and Translational Presentations of pre|CISION® Platform Candidates at the 2026 AACR Annual Conference Investors | Therapeutics
16 Mar 2026 Avacta announces opening of Phase 1 trial for second pipeline asset, FAP-Exd (AVA6103) a sustained-release pre|CISION® exatecan peptide-drug conjugate Investors | Therapeutics
24 Feb 2026 Research & Development Spotlight Series, Episode 14 Investors | R&D Spotlights Series | Therapeutics
24 Feb 2026 Avacta’s pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis Investors | Therapeutics
03 Feb 2026 Avacta announces two key clinical updates to its faridoxorubicin program Investors | Therapeutics
21 Jan 2026 Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103) Investors | Therapeutics
18 Dec 2025 Research & Development Spotlight Series, Episode 13 Podcasts and Videos | R&D Spotlights Series | Therapeutics